Allogene Therapeutics, Inc. (NASDAQ:ALLO)
| Market Cap | $217.48M-53.5% |
| Revenue (ttm) | $4.64M |
| Net Income | -$174.46M+17.7% |
| EPS | -$0.63+35.7% |
| Shares Out | 346.47M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,579,436 |
| Open | $0.65 |
| Previous Close | $0.67 |
| Day's Range | $0.62 - $0.67 |
| 52-Week Range | $0.62 - $4.46 |
| Beta | 0.48 |
| Analysts | Buy |
| Price Target | $6.43(+924.37%) |
| Earnings Date | Mar 11, 2027 |
About ALLO
Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy. This candidate is being developed, manufactured, and prepared for market release to address relapsed/refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (ALL) in both children and adults. The company's portfolio also encompasses ALLO-501, an anti-CD19 allogeneic CAR T-cell candidate currently in Phase I clinical trials for R/R non-Hodgkin lymphoma. A related therapeutic, ALLO-501A, is progressing through Phase I/II studies, targeting R/R large B-cell lymphoma or transformed follicular lymphoma. Furthermore, Allogene is advancing several other promising candidates: ALLO-715, an allogeneic CAR T-cell therapy in Phase I for R/R multiple myeloma; ALLO-605, another allogeneic CAR T-cell designed for multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody. Their investigational therapies also include those targeting CD70 for renal cell cancer, ALLO-819 (an allogeneic CAR T-cell treatment) for acute myeloid leukemia, and DLL3 for small cell lung cancer and other aggressive neuroendocrine tumors. Allogene maintains a robust network of strategic alliances, which includes licensing and collaboration agreements with organizations such as Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. They also hold a clinical trial collaboration with SpringWorks Therapeutics, Inc. Additionally, a strategic partnership with The University of Texas MD Anderson Cancer Center supports the preclinical and clinical evaluation of their allogeneic CAR T-cell product pipeline. Founded in 2017, the company's corporate headquarters are located in South San Francisco, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 11, 2027Earnings report
$ALLO stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ALLO holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ALLO's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ALLO Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ALLO Revenue by Segment
| Payroll | $15.40M | 34.12% |
| Cema-cel | $13.95M | 30.90% |
| Facilities & IT-related spend | $6.99M | 15.48% |
| Supporting external spend | $5.73M | 12.69% |
| All other development costs | $3.07M | 6.80% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New ALLO patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ALLO from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ALLO
| VTIVanguard Morningstar Total Stock Market ETF | $8.06M |
| XBIState Street SPDR S&P Biotech ETF | $6.33M |
| IWMiShares Russell 2000 ETF | $4.47M |
| VXFVanguard Extended Market ETF | $3.70M |
| VTWOVanguard Russell 2000 ETF | $1.84M |
| IWNiShares Russell 2000 Value ETF | $1.55M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from ALLO’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
-45.0 since Aug 26Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| CNCR | Loncar Cancer Immunotherapy ETF | 3.29% |
| MOON | Direxion Moonshot Innovators ETF | 2.37% |
| NIFE | Direxion Fallen Knives ETF | 0.99% |
| WDNA | WisdomTree BioRevolution Fund | 0.37% |
| BBC | Virtus Biotech Clinical Trials ETF | 0.35% |
| SBIO | ALPS Medical Breakthroughs ETF | 0.19% |
| PQSG | PGIM ETF Trust - PGIM QMA Strategic Alpha Small-Cap Growth ETF | 0.13% |
| BUSM | EA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | 0.09% |
| TMED | T. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF | 0.09% |
| XBI | State Street SPDR S&P Biotech ETF | 0.08% |
| VFMO | Vanguard U.S. Momentum Factor ETF | 0.07% |
| MEDX | Horizon Kinetics Medical ETF | 0.07% |
Weight is the stock’s share of each fund’s holdings.
